Posts tagged Master Protocols Guidance.
Blogs
6 minute read
On September 28, 2018, the U.S. Food and Drug Administration (FDA) released two draft guidances for industry. The purpose, according to FDA Commissioner Scott Gottlieb, M.D., is to modernize the approach to clinical trial design in efforts to (1) make clinical trials more efficient while maintaining patient safety and (2) increase the amount of information concerning product safety and benefits. The two draft guidances are entitled: “Master Protocols – Efficient Clinical Trial Design Strategies to Expedite Development of Cancer Drugs and Biologics” and “Adaptive ...
Blog Editors
Recent Updates
- Novel AI Laws Target Companion AI and Mental Health
- EDPA Ramps Up Its White-Collar Enforcement Framework
- California Governor Signs AB 1415 Compromise Legislation Regulating Private Equity and Hedge Fund Activity
- DOJ’s Final Rule on Bulk Data Transfers: The First 180 Days
- California Governor Signs SB 351, Strengthening the State’s Corporate Practice of Medicine Doctrine